Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who are able to give written consent and follow the study requirements
- People whose cancer can be measured using standard imaging criteria (called RECIST v1.1)
- People with advanced or metastatic stomach, gastroesophageal junction, biliary tract, or pancreatic cancer — with specific treatment history requirements depending on which part of the trial a person is being considered for (confirm with trial site for the relevant group)
- People who are able to provide a tumour tissue sample (either a fresh biopsy or stored tissue) for testing; for Parts C and D, the tumour must show a minimum level of a protein called CLDN18.2 (confirm with trial site)
- People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity)
- People with adequate organ function confirmed through blood tests at the start of the study
Who may not be able to join:
- Women who are pregnant or currently breastfeeding
- Women who are able to become pregnant and are not using adequate contraception
- People who have an active autoimmune disease that has needed systemic (whole-body) medical treatment within the past 2 years
- People currently taking corticosteroids or other immune-suppressing medications within 14 days before starting the study treatment
- People with a history of non-infectious lung inflammation (pneumonitis) that required steroid treatment, current pneumonitis, a history of scarring lung disease (interstitial lung disease), or lung scarring following COVID-19 pneumonia
- People who have untreated cancer spread to the brain or central nervous system, or brain/CNS metastases that are getting worse
- People who have previously received treatments targeting proteins called CLDN18.2, CD47, or SIRPα (note: prior treatment with zolbetuximab may be allowed in one specific group — confirm with trial site)
- People with significant heart problems or impaired heart function
- People who have had a condition involving the breakdown of red blood cells (hemolytic anaemia or Evans Syndrome) within the last 3 months
- People with active serious digestive or abdominal complications, such as a hole in the stomach wall, blocked bowel or bile duct, or fluid build-up in the chest or abdomen requiring medical intervention
- People who have had a serious blood clot, such as a deep vein thrombosis (DVT) or a clot in the lungs (pulmonary embolism), within the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 858-766-0852
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.; To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.; To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.